APA (7th ed.) Citation

M, H., YZ, J., Y, G., L, F., XY, L., Y, L., . . . ZM, S. (2024). Intensive chemotherapy versus standard chemotherapy among patients with high risk, operable, triple negative breast cancer based on integrated mRNA-lncRNA signature (BCTOP-T-A01): Randomised, multicentre, phase 3 trial. BMJ (Clinical research ed.), 387, e079603. https://doi.org/10.1136/bmj-2024-079603

Chicago Style (17th ed.) Citation

M, He, et al. "Intensive Chemotherapy Versus Standard Chemotherapy Among Patients with High Risk, Operable, Triple Negative Breast Cancer Based on Integrated MRNA-lncRNA Signature (BCTOP-T-A01): Randomised, Multicentre, Phase 3 Trial." BMJ (Clinical Research Ed.) 387 (2024): e079603. https://doi.org/10.1136/bmj-2024-079603.

MLA (9th ed.) Citation

M, He, et al. "Intensive Chemotherapy Versus Standard Chemotherapy Among Patients with High Risk, Operable, Triple Negative Breast Cancer Based on Integrated MRNA-lncRNA Signature (BCTOP-T-A01): Randomised, Multicentre, Phase 3 Trial." BMJ (Clinical Research Ed.), vol. 387, 2024, p. e079603, https://doi.org/10.1136/bmj-2024-079603.